Can Schools Require the COVID-19 Vaccine? Education, Equity, and the Courts
Given the potential legal challenges policymakers may face, legislation to remedy the COVID-19 educational crisis must be carefully drafted.
research
-
Read more: Can Schools Require the COVID-19 Vaccine? Education, Equity, and the Courts -
Read more: How Can Policymakers Encourage COVID-19 Vaccine Trials for Children? How Can Policymakers Encourage COVID-19 Vaccine Trials for Children?
We explain why COVID-19 vaccines are only just starting to be tested in children and what policymakers can do to spur pediatric vaccine trials.
-
Read more: Seniors’ Perspectives on Dementia and Decision-Making Seniors’ Perspectives on Dementia and Decision-Making
The study, which involved an online survey of and interviews with older adults, revealed a heterogeneity of ways of thinking about capacity.
-
Read more: COVID-19 and the FDA Emergency Use Authorization Power COVID-19 and the FDA Emergency Use Authorization Power
This blog post provides an overview of the FDA’s emergency authorization powers and analyzes the extent of their usage in the COVID-19 pandemic.
-
Read more: How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process? How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process?
Pharmaceutical companies are now also engaging the public themselves in an attempt to build trust in their products.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Selections feature topics ranging from political pressures facing the FDA, to the financial incentive structure for antibiotic development.
-
Read more: The Cost of Exclusion in Psychedelic Research The Cost of Exclusion in Psychedelic Research
The lack of diversity among research participants can have significant consequences on generalizability and distribution of treatments.
-
Read more: What Psychedelic Research Can Learn from Science, and What It Can Teach What Psychedelic Research Can Learn from Science, and What It Can Teach
The field has a frustrating tendency to make lofty claims about psychedelics that stray from the realities and limitations of the data.
-
Read more: COVID-19’s Impact on Clinical Trials: Meeting Participants Where They Are COVID-19’s Impact on Clinical Trials: Meeting Participants Where They Are
In light of COVID-19, a site and sponsor’s ability to flex to “meet the participant where they are” will be critical to the conduct of clinical trials.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on pharma, health law, and policy issues from August 2020.
